Trial reportClinical epigenetics2019
Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes.
Trial report in Clinical epigenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02877277 (Restoring Physiological Vitamin C Levels to the Normal Range), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Restoring Physiological Vitamin C Levels to the Normal Range: Influence on Epigenetic Regulation in Normal and Malignant Hematopoiesis
Who cites it
51 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Vitamin C boosts DNA demethylation in TET2 germline mutation carriers.Clinical epigenetics · 2023Trial
- DNA methyltransferase inhibitors in hematological malignancies and solid tumors.International journal of cancer · 2026Review
- Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation.Cell reports · 2025Article
- Antioxidant Food Supplementation in Cancer: Lessons from Clinical Trials and Insights from Preclinical Studies.Antioxidants (Basel, Switzerland) · 2025Review
- Vitamin C deficiency in allogeneic hematopoietic cell transplantation recipients in the peri-transplant period.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Management of Myeloproliferative Neoplasms: An Integrative Approach.Journal of clinical medicine · 2025Review
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- Unveiling vitamin C: A new hope in the treatment of diffuse large B‑cell lymphoma (Review).International journal of oncology · 2025Review
- Colorectal cancer progression to metastasis is associated with dynamic genome-wide biphasic 5-hydroxymethylcytosine accumulation.BMC biology · 2025Article
- The physiological functions of ascorbate in the development of cancer.Disease models & mechanisms · 2025Review
- Exploring the Ascorbate Requirement of the 2-Oxoglutarate-Dependent Dioxygenases.Journal of medicinal chemistry · 2025Review
- Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.Haematologica · 2025Review
- Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.Cancers · 2024Review
- Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024Review
- Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation.Blood cancer journal · 2024Article
- Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy.Journal of personalized medicine · 2024Review
- Micronutrient regulation of the DNA methylome.Frontiers in epigenetics and epigenomics · 2024Review
- Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins.International journal of molecular sciences · 2023Article
- Vitamin C deficiency in patients with acute myeloid leukemia: a case series and review of the literature.Blood advances · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundPatients with haematological malignancies are often vitamin C deficient, and vitamin C is essential for the TET-induced conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), the first step in active DNA demethylation. Here, we investigate whether oral vitamin C supplementation can correct vitamin C deficiency and affect the 5hmC/5mC ratio in patients with myeloid cancers treated with DNA methyltransferase inhibitors (DNMTis).
resultsWe conducted a randomized, double-blinded, placebo-controlled pilot trial (NCT02877277) in Danish patients with myeloid cancers performed during 3 cycles of DNMTi-treatment (5-azacytidine, 100 mg/m
conclusionsNormalization of plasma vitamin C by oral supplementation leads to an increase in the 5hmC/5mC ratio compared to placebo-treated patients and may enhance the biological effects of DNMTis. The clinical efficacy of oral vitamin C supplementation to DNMTis should be investigated in a large randomized, placebo-controlled clinical trial.
trial registrationClinicalTrials.gov, NCT02877277 . Registered on 9 August 2016, retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.